ライフサイエンスコーパス: stomach cancer

1 health, and is associated with incidence of stomach cancer.

2 lication for non-invasive early diagnosis of stomach cancer.

3 prevalent in survivorship of esophageal and stomach cancer.

4 and abolished G1 phase cell cycle arrest in stomach cancer.

5 genes that are significantly associated with stomach cancer.

6 that CD177 is a novel prognostic factor for stomach cancer.

7 as he read on the Internet that it can cause stomach cancer.

8 rectal cancer, and 16% (95% CI: 9%, 22%) for stomach cancer.

9 velopment of duodenal and gastric ulcers and stomach cancer.

10 phoma, ovarian cancer, pancreatic cancer, or stomach cancer.

11 ustry and the risks of esophageal cancer and stomach cancer.

12 eloid leukemia, cleidocranial dysplasia, and stomach cancer.

13 er), with a notably high frequency of 11% in stomach cancer.

14 n potentially be used for early diagnosis of stomach cancer.

15 ts for developing lncRNA-based therapies for stomach cancer.

16 adder, esophagus, colon, lung, pancreas, and stomach cancers.

17 n 73% of those with bladder, pancreatic, and stomach cancers.

18 er, ovarian, pancreatic, small cell lung, or stomach cancers.

19 instability-positive endometrial, colon, and stomach cancers.

20 obacter pylori is responsible for most human stomach cancers.

21 -3.90), pancreatic cancer (2.35, 1.91-2.88), stomach cancer (1.96, 1.65-2.34), and lung cancer (1.68,

22 ratios were 5.76 (95% CI, 2.12 to 15.6) for stomach cancer, 3.61 (95% CI, 1.33 to 9.79) for kidney c

23 BRCA2 mutation carriers are also at risk of stomach cancer and melanoma (of the skin and eye).

24 of cagA+ s1-type vacA H. pylori in cases of stomach cancer and ulcers as opposed to cases of gastrit

25 Risks of ovarian, breast, and stomach cancers and leukemias/lymphomas were increased n

26 s overexpressed in blood, breast, colon, and stomach cancers and promotes cell survival in the face o

27 ciations with violent and accidental deaths, stomach cancer, and alcohol- and smoking-related outcome

28 for ovarian cancer mortality (OR = 1.6), 2) stomach cancer as a risk factor for ovarian cancer morta

29 s in mortality from cerebrovascular disease, stomach cancer, colorectal cancer, lung cancer, breast c

30 developed a phylogenetic model for analyzing stomach cancer data.

31 The phylogenetic model was applied to the stomach cancer data.

32 phageal cancer and 646 workers with incident stomach cancer diagnosed between 1989 and 1998 were comp

33 und a decreased risk of cancer, particularly stomach cancer, for participants taking a multivitamin s

34 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and

35 take are known as important risk factors for stomach cancer in humans.

36 s mutually and separately for colorectal and stomach cancers in relation to consumption of exclusivel

37 Treatment-related stomach cancer is an important cause of morbidity and mo

38 , the underlying mechanism of lncRNA GAS5 in stomach cancer is poorly understood.

39 Stomach cancer is the second most common cause of cancer

40 0.32; 95% CI, 0.27 to 0.39; P trend < .001), stomach cancer (men: HR, 0.87; 95% CI, 0.82 to 0.93; P t

41 eported to be a protective factor for either stomach cancer or esophageal cancer and therefore warran

42 o (OR) = 1.9), colorectal cancer (OR = 1.6), stomach cancer (OR = 1.9), and lung cancer (OR = 1.7).

43 both esophageal cancer (p-trend = 0.01) and stomach cancer (p-trend < 0.001) when exposures were lag

44 and tumor) were sequenced from each of five stomach cancer patients in different stages (I, II, III

45 ake and plant-based foods seem promising for stomach cancer prevention, while vitamin C lowers the ri

46 Treatment with dacarbazine also increased stomach cancer risk (12 cases, nine controls; OR, 8.8; 9

47 (>/= 5,600 mg/m(2)) had strikingly elevated stomach cancer risk (25 cases, two controls; odds ratio

48 Stomach cancer risk increased with increasing radiation

49 ry groups in risks of the following cancers: stomach cancer [RRs (95% CIs) compared with meat eaters:

50 g into the 5'-UTR of four proto-oncogenes in stomach cancer sequencing data.

51 For stomach cancer, the random-effects RR estimate was 0.53

52 In the meta-analyses of colorectal and stomach cancer, the reference categories ranged from no

53 und that lncRNA GAS5 had lower expression in stomach cancer tissues than the normal counterparts.

54 Stomach cancer was the country's leading cause of cancer

55 therapy had dose-dependent increased risk of stomach cancer, with marked risks for patients who also

56 ies for specific delivery of therapeutics to stomach cancer without damaging normal cells and tissues

57 produce major regressions of pancreatic and stomach cancer xenografts.